Abstract
The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
Original language | English |
---|---|
Patent number | DK2408468T3 |
IPC | C07K 16/ 28 A I |
Priority date | 18/03/10 |
State | Published - 21 Jul 2014 |